A number of preclinical cancer experiments performed extensive investigations on the potential of IL-15 as an antitumor agent that is mediated by NK cells and T lymphocytes, which recently entered trial studies for the mediation of cancer regression (15, 77, 89). This evidence concerns the gene IL15 and cancer.